18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial - The Lancet
Por um escritor misterioso
Descrição
PDF) Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial
Clinical practice in prostate PET imaging - Sean J. Huls, Brian Burkett, Eric Ehman, Val J. Lowe, Rathan M. Subramaniam, A. Tuba Kendi, 2023
Axumin LOCATE Trial Results Axumin® (fluciclovine F 18) Injection
PET Radiotracer Boosts Survival in Postprostatectomy Salvage Radiotherapy
Improvements in Prostate Cancer Management: Focus on Imaging and Treatment - European Medical Journal
Mask R-CNN assisted 2.5D object detection pipeline of 68Ga-PSMA-11 PET/CT-positive metastatic pelvic lymph node after radical prostatectomy from solely CT imaging
Prostate Cancer: Clinical Implications From the EMPIRE-1 Trial
Imaging in Prostate Cancer: An Update on a Rapidly Changing Space
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management
The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis‐free survival in patients with relapsed prostate cancer following prostatectomy - Lee - 2023 - The Prostate - Wiley Online Library
Clinical practice in prostate PET imaging - Sean J. Huls, Brian Burkett, Eric Ehman, Val J. Lowe, Rathan M. Subramaniam, A. Tuba Kendi, 2023
Axumin LOCATE Trial Results Axumin® (fluciclovine F 18) Injection
Frontiers Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada
de
por adulto (o preço varia de acordo com o tamanho do grupo)
